Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
The following slides are notes made by David Doherty
following a very interesting presentation on “Pricing and
evaluating ...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Hor...
Upcoming SlideShare
Loading in …5
×

Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Horizon Pharma PLC $HZNP

280 views

Published on

The following slides are notes made by David Doherty following a very interesting presentation on “Pricing and evaluating Orphan Drugs – present and future” provided by Goran Medic, Market Access Manager Europe at Horizon Pharma Plc at the Pharma Pricing & Market Access Europe Conference in London (the world’s largest gathering of pharmaceutical pricing, market access and reimbursement professionals) on the 23rd February 2017.

Published in: Law
  • Be the first to comment

  • Be the first to like this

Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future” by the European Market Access Manager at Horizon Pharma PLC $HZNP

  1. 1. The following slides are notes made by David Doherty following a very interesting presentation on “Pricing and evaluating Orphan Drugs – present and future” provided by Goran Medic, Market Access Manager Europe at Horizon Pharma Plc at the Pharma Pricing & Market Access Europe Conference in London (the world’s largest gathering of pharmaceutical pricing, market access and reimbursement professionals) on the 23rd February 2017.

×